Evidence map›Paper›PMID 37908013›Full record

ArticleClinical diabetes and endocrinology2023

Pituitary macroadenomas in childhood and adolescence: a clinical analysis of 7 patients.

Cristina Aguilar-Riera, María Clemente, Núria González-Llorens, Eduard Mogas, Ariadna Campos-Martorell, Anna Fàbregas, Betina Biagetti, Elida Vázquez, Diego Yeste

Open access · goldAbstract read
In one paragraph

Article in Clinical diabetes and endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Observational
  2. Article
  3. Macroprolactinoma in an adolescent female with primary amenorrhoea.Endocrinology, diabetes & metabolism case reports · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Cristina Aguilar-RieraPediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain. c_aguilarriera@hotmail.com.ORCID http://orcid.org/0000-0001-5256-3743
María ClementePediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Núria González-LlorensPediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Eduard MogasPediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Ariadna Campos-MartorellPediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Anna FàbregasPediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Betina BiagettiEndocrinology and Nutrition Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Elida VázquezPediatric Radiology Service, Hospital Universitari, Vall d'Hebron, Barcelona, Spain.
Diego YestePediatric Endocrinology Service, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Vall d'Hebron Hospital Universitari · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPituitary adenomas (PPAs) are uncommon in childhood and adolescence, accounting for 2-6% of all intracranial neoplasms. Delayed puberty, growth retardation, galactorrhea and weight gain are common features at presentation in pediatric patients. Functional tumors constitute a vast majority (90%) of PPAs, with the most frequent being prolactinomas. CASE PRESENTATION: A retrospective review of the clinical features and outcomes of 7 pediatric patients with pituitary macroadenomas was conducted. We included PPAs in patients under 18 years at diagnosis with diameters larger than 10 mm by magnetic resonance (MRI). Six patients were males (85%), with age at diagnosis ranging from 8 to 15 (median 14 ± 2.8SDS). The primary symptoms that led to medical attention were growth retardation, gigantism and secondary amenorrhea. The visual field was reduced in three cases (42%). Suprasellar extension was present in 3 subjects, and one had a giant adenoma. Adenomas were clinically functioning in 6 patients (85%) (three prolactinomas, two somatropinomas, one secreting FSH and one no-producer). The prolactinomas responded to treatment with cabergoline. For the rest, one required transsphenoidal surgery and the other three both surgery and radiotherapy. All patients undergoing radiotherapy had secondary panhypopituitarism. In relation to the genetic studies, two patients presented a pathogenic mutation of the AIP gene and one of the MEN1. DISCUSION AND

conclusionPediatric pituitary macroadenomas are a distinct entity, mostly found in males and with a predominance of functional tumors leading to detrimental effects on growth and puberty in addition to neuro-ophthalmological manifestations. It is important to perform genetic studies in patients with macroadenomas appearing under the age of 18 years as genetic and syndromic associations are more frequent in this age group.

Indexed as

AdolescentCabergolineChildGenetic analysisMacroadenomaTranssphenoidal

Identifiers

PMID37908013
PMCPMC10619272
OpenAlexW4388073502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.